Skip to main content

The Medicinal Potential of Influenza Virus Surface Proteins: Hemagglutinin and Neuraminidase

Buy Article:

$63.00 plus tax (Refund Policy)


Nowadays, influenza virus is still a big threat to human. Hemagglutinin (HA) and neuraminidase (NA) are the two viral surface proteins, which play important roles in the life cycle of influenza virus. Current influenza vaccines and anti-influenza drugs work mainly by interfering with the functions of the two proteins. In this review, we will display some recent studies about the two proteins. As to HA, this review covers a lot including its fusion function, receptor specificity, antigenic shift hypothesis, novel antibodies and various inhibitors in order to deeply discuss this protein. As to NA, this review mainly focuses on studies about the newly identified 150-cavity of group-1 NAs and shows some untypical NA inhibitors aiming to provide a broader range of lead compounds for anti-influenza drug design.

Keywords: Antibody; anti-influenza drugs; antigenic shift; group-1 NAs; hemagglutinin; influenza; inhibitor; membrane fusion; neuraminidase; receptor specificity

Document Type: Research Article


Publication date: 2011-03-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more